Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma

This study has been completed.
Information provided by (Responsible Party):
Eli Lilly and Company Identifier:
First received: January 21, 2011
Last updated: May 8, 2015
Last verified: May 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: March 2015
  Primary Completion Date: February 2015 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: May 8, 2015